Thyroid cancer drug safety tracked in large Real-World study
NCT ID NCT02185560
First seen Mar 10, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study monitors the safety and side effects of the drug sorafenib (Nexavar) in people with a type of advanced thyroid cancer that cannot be removed by surgery. Over 450 participants are being followed for up to 2 years to track side effects, how long they stay on treatment, and survival. The study does not test a new treatment but collects real-world information on how the drug performs in routine medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Multiple Locations, Japan
Conditions
Explore the condition pages connected to this study.